<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939301</url>
  </required_header>
  <id_info>
    <org_study_id>Kline-1UM NO for PE</org_study_id>
    <secondary_id>1UM1HL113203-01A1</secondary_id>
    <nct_id>NCT01939301</nct_id>
  </id_info>
  <brief_title>Nitric Oxide to Treat Pulmonary Embolism</brief_title>
  <official_title>Randomized Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas, Southwestern Medical Center at Dallas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study to treat subjects diagnosed with pulmonary embolism with inhaled
      nitric oxide or placebo (oxygen).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind study to treat subjects diagnosed with pulmonary embolism
      with inhaled nitrix oxide. In this clinical trial investigators will randomized patients to
      receive inhaled nitric oxide or sham (nitrogen + oxygen) for 24 hours. Patients must have a
      submassive pulmonary embolism (PE) and evidence of right ventricular (RV) heart dysfunction.
      Investigators hypothesize that the administration of inhaled NO + oxygen to patients with
      severe submassive PE will improve RV function, reduce RV strain and necrosis and improve
      dyspnea (difficulty breathing) more than sham oxygen treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">October 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Normal Right Ventricular (RV) Function and Viability</measure>
    <time_frame>5 days or hospital discharge (whichever occurs first)</time_frame>
    <description>Right ventricular (RV) function and viability assessed by the composite of normal RV size (&lt;42 mm in diastole) and tricuspid annular plane systolic excursion (TAPSE) &gt; 16 mm and normal right ventricular index of myocardial performance (RIMP) &lt; 0.40 using spectral Doppler or &lt; 0.55 using tissue Doppler) and normal fractional area change (FAC) (&gt; 33%) and a serum hsTnT &lt; 14pg/mL. Missing values will be considered normal.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled nitric oxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oxygen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Nitric Oxide</intervention_name>
    <description>Nitric Oxide + oxygen</description>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Nitrogen + Oxygen</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
    <other_name>oxygen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18

          -  Pulmonary imaging-proven PE, as interpreted by local radiologist

          -  At least one predictor of RV dysfunction:

               1. echocardiography with RV dilation or hypokinesis,

               2. estimated RVSP &gt;40mm HG,

               3. RV&gt;LV on CTPA,

               4. elevated troponin I (&gt;0.1 ng/mL) or natriuretic peptide (BNP &gt; 90 pg/mL),

               5. screening bedside cardiac ultrasound with color flow capability that shows RV
                  dysfunction,

               6. RV strain on ECG

          -  Plan to admit to a bed with telemetry capability

        Exclusion Criteria:

          -  Vasopressor support at time of enrollment

          -  Pregnancy

          -  Plan by clinical care team to use lytic or surgical embolectomy

          -  Plan by clinical team to use platelet inhibiting drugs

          -  Contraindication to anticoagulation

          -  Altered mental status such that the patient is unable to provide informed consent

          -  Inability to use a nasal cannula or face mask

          -  Comfort care measures instituted

          -  Supplemental oxygen requirements greater than can be administered via nasal cannula in
             order to maintain Sa)2 &gt; 80%

          -  Pneumothorax with decompression

          -  Serum MetHb &gt; 10%

          -  Recent use of drugs known to increase cGMP

          -  Use of nitroprusside or nitroglycerin within the last 4 hours

          -  Use of any other nitrates with in the past 24 hours

          -  Use of a fibrinolytic medicine within the past 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff A Kline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eskenazi Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>36216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <results_first_submitted>January 23, 2018</results_first_submitted>
  <results_first_submitted_qc>March 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2018</results_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jeffrey Kline</investigator_full_name>
    <investigator_title>Vice Chair of Research</investigator_title>
  </responsible_party>
  <keyword>Pulmonary embolism clot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled nitric oxide
Nitric Oxide + oxygen</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>oxygen
Nitrogen + Oxygen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled nitric oxide
Nitric Oxide + oxygen</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>oxygen
Nitrogen + Oxygen</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="15"/>
                    <measurement group_id="B2" value="59" spread="16"/>
                    <measurement group_id="B3" value="57" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Normal Right Ventricular (RV) Function and Viability</title>
        <description>Right ventricular (RV) function and viability assessed by the composite of normal RV size (&lt;42 mm in diastole) and tricuspid annular plane systolic excursion (TAPSE) &gt; 16 mm and normal right ventricular index of myocardial performance (RIMP) &lt; 0.40 using spectral Doppler or &lt; 0.55 using tissue Doppler) and normal fractional area change (FAC) (&gt; 33%) and a serum hsTnT &lt; 14pg/mL. Missing values will be considered normal.</description>
        <time_frame>5 days or hospital discharge (whichever occurs first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled nitric oxide
Nitric Oxide + oxygen</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>oxygen
Nitrogen + Oxygen</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Normal Right Ventricular (RV) Function and Viability</title>
          <description>Right ventricular (RV) function and viability assessed by the composite of normal RV size (&lt;42 mm in diastole) and tricuspid annular plane systolic excursion (TAPSE) &gt; 16 mm and normal right ventricular index of myocardial performance (RIMP) &lt; 0.40 using spectral Doppler or &lt; 0.55 using tissue Doppler) and normal fractional area change (FAC) (&gt; 33%) and a serum hsTnT &lt; 14pg/mL. Missing values will be considered normal.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled nitric oxide
Nitric Oxide + oxygen</description>
        </group>
        <group group_id="E2">
          <title>Sham</title>
          <description>oxygen
Nitrogen + Oxygen</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>arrhythmia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey A. Kline, MD</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-880-3900</phone>
      <email>jefkline@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

